Keywords: BioMarin, LEMS, Firdapse, Genmab, GlaxoSmithKline, Arzerra
BioMarin launches LEMS drug Firdapse in European Union; and Genmab gets conditional approval for Arzerra
Article | 20 April 2010
California, USA-based BioMarin Pharmaceutical says that Firdapse (3,4-diaminopyridine) is now commercially available in the European Union for the treatment of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
